Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population Meeting Abstract
| Authors: | Mellinghoff, I. K.; Peters, K. B.; Cloughesy, T. F.; Burris, H. A. 3rd; Maher, E. A.; Janku, F.; Cote, G. M.; De La Fuente, M. I.; Clarke, J. L.; Kha, L.; Li, L.; Yuen, M.; Arnofsky, M.; Hassan, I.; Steelman, L.; Pandya, S. S.; Wen, P. Y. |
| Abstract Title: | Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368301199 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.2504 |
| Notes: | Meeting Abstract: 2504 -- Source: Wos |
